XNASSKYE
Market cap80mUSD
Jan 17, Last price
2.66USD
1D
-1.48%
1Q
-42.55%
IPO
-5.00%
Name
Skye Bioscience Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
67.85%
Rev. gr., 5y
%
Revenues
0k
Net income
-38m
L+93.23%
CFO
-14m
L+9.48%
Earnings
Mar 19, 2025
Profile
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 13,672 | 12,221 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (13,672) | (12,221) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 4 | 7 | |||||||
Tax Rate | |||||||||
NOPAT | (13,675) | (12,228) | |||||||
Net income | (37,645) 93.23% | (19,482) 128.60% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 11,735 | 2 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 4,444 | 1,927 | |||||||
Long-term debt | 414 | 79 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,749 | ||||||||
Net debt | 3,602 | 761 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (13,952) | (12,744) | |||||||
CAPEX | (13) | (28) | |||||||
Cash from investing activities | 6,596 | 5,214 | |||||||
Cash from financing activities | 16,443 | (209) | |||||||
FCF | (15,983) | (10,904) | |||||||
| Balance | |||||||||
Cash | 1,256 | 1,245 | |||||||
Long term investments | |||||||||
Excess cash | 1,256 | 1,245 | |||||||
Stockholders' equity | (104,370) | (65,824) | |||||||
Invested Capital | 106,854 | 64,743 | |||||||
ROIC | |||||||||
ROCE | 1,130.59% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 7,006 | 1,984 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (13,548) | (12,106) | |||||||
EV/EBITDA | |||||||||
Interest | 906 | 665 | |||||||
Interest/NOPBT | |||||||||